Jim Hoffman: Exploring Extracorporeal Strategies to Target NETs in Cardiovascular Disease
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared Apherese ForschungsInstitut – AFI’s post on LinkedIn, adding:
”Lp(a) does not act alone to help facilitate potentially life-threatening occlusive atheromas. Other factors, such as NETosis dysfunction and poor NET clearance, are likely at play, increasing the risk of CVD, heart failure, MI, and strokes.
Here are two other extracorporeal methods that target elevated extracellular chromatin/NETs that I believe should be trialed for potentially reversing diet and drug-refractory atherogenesis. They are simpler to perform and could be more efficacious than H.E.L.P. apheresis and other extracorporeal methods of lipid lowering.
A Novel Role for Lipoprotein(a) in Potentiating Neutrophil Extracellular Trap Formation.
More research linking NETosis dysfunction to atherosclerosis progression and atheroma development can be found
Quoting Apherese ForschungsInstitut – AFI’s post:
”Elevated Lipoprotein(a) is a major, genetically determined driver of cardiovascular risk, yet it remains largely untouched by traditional lifestyle changes and statins.
A recent review in the European Heart Journal titled ‘Lipoprotein(a)-lowering therapies: a promising future’ highlights the evolving landscape of treatment.
At the Apherese Forschungsinstitut, we closely follow these developments. Phase III trials of RNA-based therapies specifically targeting Lp(a) are currently underway. Until these new drugs reach the market and prove long-term outcomes, Lipoprotein Apheresis continues to be the life-saving ‘gold standard’ for patients with extreme Lp(a) elevation and progressive ASCVD.
In the current therapeutic landscape, Lipoprotein Apheresis remains the only established and highly effective method to significantly reduce Lp(a) levels and mitigate cardiovascular events in high-risk patients.”
Title: Lipoprotein(a)-lowering therapies: a promising future
Authors: Jingwen Zhang, Ann Marie Navar, Lale Tokgozoglu
Read the Full Article on Apherese ForschungsInstitut – AFI
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 9, 2026, 15:24Zeeshan Ahmed Khattak: Certification Pathways in Anticoagulation for Pharmacists
-
Mar 9, 2026, 15:20Anthony Yazbeck։ The ‘Golden Blood’ – The World’s Rarest Blood Type
-
Mar 9, 2026, 15:13Ali Al Janaahi: Clinical Insights on Recurrent Stroke in Neuro‑Behçet Disease at DINC 2026
-
Mar 9, 2026, 14:39Tareq Abadl: Quick Clinical Interpretation of Hepatitis B Markers
-
Mar 9, 2026, 14:32Sumedha Dash: What Happens Before a Blood Bag Reaches the Patient?
-
Mar 9, 2026, 14:26Augustina Isioma Ikusemoro: Women Powering the Future of Blood Transfusion
-
Mar 9, 2026, 14:10Jecko Thachil: The Journey of Protamine – From Heparin Reversal to Potential Gene Therapy Applications
-
Mar 9, 2026, 14:10Advocating for the Bleeding Disorders Community at NBDF 2026 Washington Days – Hemophilia of Georgia
-
Mar 9, 2026, 14:05Ramy Abdelnaby: The Impact of Multiterritory Brain Infarcts on Recurrent Stroke Risk and Anticoagulation Efficacy